U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23FN4O3
Molecular Weight 434.4637
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLAPARIB

SMILES

c1ccc2c(c1)c(Cc3ccc(c(c3)C(=O)N4CCN(CC4)C(=O)C5CC5)F)nnc2O

InChI

InChIKey=FDLYAMZZIXQODN-UHFFFAOYSA-N
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880823/

Olaparib is an oral inhibitor of poly (ADP-ribose) polymerase enzymes, including PARP1, PARP2, and PARP3 which are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has shown activity in ovarian and breast tumors with known BRCA mutations and was the first FDA approved drug in this class. Lynparza (olaparib) is indicated for treatment of gBRCA-mutated advanced ovarian cancer. Its use together with other chemotherapy medicines can lead to increased effects on the blood resulting in reduction in the numbers of white blood cells and platelets, and anaemia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P09874
Gene ID: 142.0
Gene Symbol: PARP1
Target Organism: Homo sapiens (Human)
1.94 nM [IC50]
Target ID: Q9UGN5
Gene ID: 10038.0
Gene Symbol: PARP2
Target Organism: Homo sapiens (Human)
Target ID: Q9Y6F1
Gene ID: 10039.0
Gene Symbol: PARP3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LYNPARZA

Approved Use

Monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Launch Date

1.4189472E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.97 μg/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.88 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.75 μg/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.27 μg/mL
300 mg 2 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.875 ug/mL
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.9 μg × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31.7 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.7 μg × h/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
44 μg × h/mL
300 mg 2 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31.68 ug*h/mL
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
43.91 ug*h/mL
300 mg 2 times / day single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
43.9499999999999 ug*h/mL
300 mg 2 times / day single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
36.37 ug*h/mL
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
36.53 ug*h/mL
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
OLAPARIB plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.17 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.52 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLAPARIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
18%
OLAPARIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources: Page: p. 8
unhealthy
n = 52
Health Status: unhealthy
Condition: advanced solid tumors
Population Size: 52
Sources: Page: p. 8
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Disc. AE: Anemia, Anemia...
AEs leading to
discontinuation/dose reduction:
Anemia (grade 1-2, 24%)
Anemia (grade 3-4, 20%)
Neutropenia (9%)
Nausea (grade 1-2, 73%)
Nausea (grade 3-4, 3%)
Vomiting (grade 1-2, 34%)
Vomiting (grade 3-4, 3%)
Sources:
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Disc. AE: Fatigue, Fatigue...
Other AEs: Diarrhea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Fatigue (grade 1-2, 62%)
Fatigue (grade 3-4, 4%)
Other AEs:
Diarrhea (grade 1-2, 31%)
Diarrhea (grade 3-4, 2%)
Abscess oral (grade 1-2, 19%)
Aphthous ulcer (grade 1-2, 19%)
Gingival abscess (grade 1-2, 19%)
Gingival disorder (grade 1-2, 19%)
Gingival pain (grade 1-2, 19%)
Gingivitis (grade 1-2, 19%)
Mouth ulceration (grade 1-2, 19%)
Mucosal infection (grade 1-2, 19%)
Mucosal inflammation (grade 1-2, 19%)
Oral candidiasis (grade 1-2, 19%)
Oral discomfort (grade 1-2, 19%)
Oral herpes (grade 1-2, 19%)
Oral infection (grade 1-2, 19%)
Oral mucosal erythema (grade 1-2, 19%)
Oral pain (grade 1-2, 19%)
Oropharyngeal discomfort (grade 1-2, 19%)
Oropharyngeal pain (grade 1-2, 19%)
Abscess oral (grade 3-4, 1%)
Aphthous ulcer (grade 3-4, 1%)
Gingival abscess (grade 3-4, 1%)
Gingival disorder (grade 3-4, 1%)
Gingival pain (grade 3-4, 1%)
Gingivitis (grade 3-4, 1%)
Mouth ulceration (grade 3-4, 1%)
Mucosal infection (grade 3-4, 1%)
Mucosal inflammation (grade 3-4, 1%)
Oral candidiasis (grade 3-4, 1%)
Oral discomfort (grade 3-4, 1%)
Oral herpes (grade 3-4, 1%)
Oral infection (grade 3-4, 1%)
Oral mucosal erythema (grade 3-4, 1%)
Oral pain (grade 3-4, 1%)
Oropharyngeal discomfort (grade 3-4, 1%)
Oropharyngeal pain (grade 3-4, 1%)
Nasopharyngitis (grade 1-4, 36%)
Sinusitis (grade 1-4, 36%)
Rhinitis (grade 1-4, 36%)
Influenza (grade 1-4, 36%)
Decreased appetite (grade 1-4, 22%)
Arthralgia (grade 1-4, 30%)
Myalgia (grade 1-4, 30%)
Dysgeusia (grade 1-4, 27%)
Headache (grade 1-2, 25%)
Headache (grade 3-4, 1%)
Rash (<20%)
Cough (<20%)
Dyspepsia (<20%)
Leukopenia (<20%)
Hypomagnesemia (<20%)
Dizziness (<20%)
Thrombocytopenia (<20%)
Creatinine increased (<20%)
Lymphopenia (<20%)
Edema (<20%)
Mean corpuscular volume increased (grade 1-4, 89%)
Decreased hemoglobin (grade 1-2, 66%)
Decreased hemoglobin (grade 3-4, 17%)
Leukocyte count decreased (grade 1-2, 64%)
Leukocyte count decreased (grade 3-4, 5%)
Lymphocyte count low (grade 1-2, 56%)
Lymphocyte count low (grade 3-4, 11%)
Absolute neutrophil count decreased (grade 1-2, 44%)
Absolute neutrophil count decreased (grade 3-4, 7%)
Creatinine serum increased (grade 1-4, 44%)
Platelets decreased (grade 1-2, 40%)
Platelets decreased (grade 3-4, 2%)
Sources:
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources: Page: p. 99
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources: Page: p. 99
Disc. AE: Thrombocytopenia, Myelodysplastic syndrome...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (9 patients)
Myelodysplastic syndrome (2 patients)
Acute myeloid leukemia (2 patients)
Sources: Page: p. 99
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Disc. AE: Nausea, Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 61%)
Nausea (grade 3-4, 3%)
Vomiting (grade 1-2, 39%)
Vomiting (grade 3-4, 4%)
Fatigue (grade 1-2, 58%)
Fatigue (grade 3-4, 8%)
Anemia (grade 1-2, 75%)
Anemia (grade 3-4, 15%)
Thrombocytopenia (grade 1-2, 27%)
Thrombocytopenia (grade 3-4, 3%)
Sources:
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Sources:
Disc. AE: Pneumonitis...
AEs leading to
discontinuation/dose reduction:
Pneumonitis (grade 5, <1%)
Sources:
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Other AEs: Anemia, Anemia...
Other AEs:
Anemia (grade 1-2, 16%)
Anemia (grade 3-4, 18%)
Abdominal discomfort (grade 1-2, 35%)
Abdominal discomfort (grade 3-4, 8%)
Decreased appetite (grade 1-2, 21%)
Decreased appetite (grade 3-4, 1%)
Diarrhea (grade 1-2, 30%)
Diarrhea (grade 3-4, 1%)
Dyspepsia (grade 1-4, 25%)
Asthenia (grade 1-2, 58%)
Asthenia (grade 3-4, 8%)
Nasopharyngitis (grade 1-4, 26%)
Arthralgia (grade 1-4, 21%)
Musculoskeletal pain (grade 1-4, 21%)
Myalgia (grade 1-4, 22%)
Neutropenia (grade 1-2, 18%)
Neutropenia (grade 3-4, 7%)
Lymphopenia (grade 1-2, 39%)
Lymphopenia (grade 3-4, 17%)
Mean corpuscular volume increased (grade 1-4, 57%)
Creatinine increased (grade 1-2, 28%)
Creatinine increased (grade 3-4, 2%)
Cough (10-20)
Constipation (10-20)
Dysgeusia (10-20)
Peripheral edema (10-20)
Back pain (10-20)
Dizziness (10-20)
Headache (10-20)
Urinary tract infection (10-20)
Dyspnea (10-20)
Rash (10-20)
Leukopenia (1-10)
Stomatitis (1-10)
Peripheral neuropathy (1-10)
Pyrexia (1-10)
Hypomagnesemia (1-10)
Hyperglycemia (1-10)
Anxiety (1-10)
Depression (1-10)
Insomnia (1-10)
Dysuria (1-10)
Urinary incontinence (1-10)
Vulvovaginal disorder (1-10)
Dry skin (1-10)
Eczema (1-10)
Pruritis (1-10)
Hypertension (1-10)
Venous thrombosis (1-10)
Hot flush (1-10)
Sources:
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 2618
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 2618
Sources:
Disc. AE: Myelodysplastic syndrome, Acute myeloid leukemia...
AEs leading to
discontinuation/dose reduction:
Myelodysplastic syndrome (grade 5, <1%)
Acute myeloid leukemia (grade 5, <1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Neutropenia 9%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Anemia grade 1-2, 24%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Vomiting grade 1-2, 34%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Nausea grade 1-2, 73%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Anemia grade 3-4, 20%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Nausea grade 3-4, 3%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Vomiting grade 3-4, 3%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
unhealthy
n = 195
Cough <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Creatinine increased <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Dizziness <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Dyspepsia <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Edema <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Hypomagnesemia <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Leukopenia <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Lymphopenia <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Rash <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Thrombocytopenia <20%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Abscess oral grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Aphthous ulcer grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival abscess grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival disorder grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival pain grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingivitis grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mouth ulceration grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mucosal infection grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mucosal inflammation grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral candidiasis grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral discomfort grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral herpes grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral infection grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral mucosal erythema grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral pain grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oropharyngeal discomfort grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oropharyngeal pain grade 1-2, 19%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Headache grade 1-2, 25%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Diarrhea grade 1-2, 31%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Platelets decreased grade 1-2, 40%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Absolute neutrophil count decreased grade 1-2, 44%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Lymphocyte count low grade 1-2, 56%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Fatigue grade 1-2, 62%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Leukocyte count decreased grade 1-2, 64%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Decreased hemoglobin grade 1-2, 66%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Decreased appetite grade 1-4, 22%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Dysgeusia grade 1-4, 27%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Arthralgia grade 1-4, 30%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Myalgia grade 1-4, 30%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Influenza grade 1-4, 36%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Nasopharyngitis grade 1-4, 36%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Rhinitis grade 1-4, 36%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Sinusitis grade 1-4, 36%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Creatinine serum increased grade 1-4, 44%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mean corpuscular volume increased grade 1-4, 89%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Abscess oral grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Aphthous ulcer grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival abscess grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival disorder grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingival pain grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Gingivitis grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Headache grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mouth ulceration grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mucosal infection grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Mucosal inflammation grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral candidiasis grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral discomfort grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral herpes grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral infection grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral mucosal erythema grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oral pain grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oropharyngeal discomfort grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Oropharyngeal pain grade 3-4, 1%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Lymphocyte count low grade 3-4, 11%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Decreased hemoglobin grade 3-4, 17%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Diarrhea grade 3-4, 2%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Platelets decreased grade 3-4, 2%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Fatigue grade 3-4, 4%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Leukocyte count decreased grade 3-4, 5%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Absolute neutrophil count decreased grade 3-4, 7%
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources:
Acute myeloid leukemia 2 patients
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources: Page: p. 99
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources: Page: p. 99
Myelodysplastic syndrome 2 patients
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources: Page: p. 99
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources: Page: p. 99
Thrombocytopenia 9 patients
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources: Page: p. 99
unhealthy
n = 195
Health Status: unhealthy
Condition: gBRCAm ovarian cancer
Population Size: 195
Sources: Page: p. 99
Thrombocytopenia grade 1-2, 27%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Vomiting grade 1-2, 39%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Fatigue grade 1-2, 58%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Nausea grade 1-2, 61%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Anemia grade 1-2, 75%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Anemia grade 3-4, 15%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Nausea grade 3-4, 3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Thrombocytopenia grade 3-4, 3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Vomiting grade 3-4, 4%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Fatigue grade 3-4, 8%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
unhealthy
n = 223
Pneumonitis grade 5, <1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Sources:
Anxiety 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Depression 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dry skin 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dysuria 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Eczema 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Hot flush 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Hyperglycemia 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Hypertension 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Hypomagnesemia 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Insomnia 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Leukopenia 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Peripheral neuropathy 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Pruritis 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Pyrexia 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Stomatitis 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Urinary incontinence 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Venous thrombosis 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Vulvovaginal disorder 1-10
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Back pain 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Constipation 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Cough 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dizziness 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dysgeusia 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dyspnea 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Headache 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Peripheral edema 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Rash 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Urinary tract infection 10-20
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Anemia grade 1-2, 16%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Neutropenia grade 1-2, 18%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Decreased appetite grade 1-2, 21%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Creatinine increased grade 1-2, 28%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Diarrhea grade 1-2, 30%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Abdominal discomfort grade 1-2, 35%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Lymphopenia grade 1-2, 39%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Asthenia grade 1-2, 58%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Arthralgia grade 1-4, 21%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Musculoskeletal pain grade 1-4, 21%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Myalgia grade 1-4, 22%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Dyspepsia grade 1-4, 25%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Nasopharyngitis grade 1-4, 26%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Mean corpuscular volume increased grade 1-4, 57%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Decreased appetite grade 3-4, 1%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Diarrhea grade 3-4, 1%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Lymphopenia grade 3-4, 17%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Anemia grade 3-4, 18%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Creatinine increased grade 3-4, 2%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Neutropenia grade 3-4, 7%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Abdominal discomfort grade 3-4, 8%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Asthenia grade 3-4, 8%
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 223
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 223
Sources:
Acute myeloid leukemia grade 5, <1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 2618
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 2618
Sources:
Myelodysplastic syndrome grade 5, <1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended|MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy
n = 2618
Health Status: unhealthy
Condition: gBRCA-mutated advanced ovarian cancer
Population Size: 2618
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no [Inhibition >100 uM]
no
no
no
no
no
yes [IC50 18.4 uM]
yes [IC50 19.9 uM]
yes [IC50 20.3 uM]
yes [IC50 37.9 uM]
yes [IC50 47.1 uM]
yes [IC50 5.5 uM]
yes [Inhibition 100 uM]
yes
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Converting cancer mutations into therapeutic opportunities.
2009 Sep
Recent advances in managing triple-negative breast cancers.
2009 Sep 28
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
2010
Triple-negative breast cancer.
2010
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.
2010
Present and future evolution of advanced breast cancer therapy.
2010
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
2010
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
2010
Targeted therapy in ovarian cancer.
2010
Targeted therapies in epithelial ovarian cancer.
2010
A current review of targeted therapeutics for ovarian cancer.
2010
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
2010
Biology-driven cancer drug development: back to the future.
2010 Apr 12
BRCA mutations in the management of breast cancer: the state of the art.
2010 Dec
Are current development programs realising the full potential of new agents?
2010 Dec 20
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
2010 Feb
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
2010 Feb 11
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
2010 Feb 15
Gateways to clinical trials.
2010 Jan-Feb
[Treatment with oral agents for breast cancer].
2010 Jul
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
2010 Jul 24
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
2010 Jul 24
Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
2010 Jun
Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.
2010 Jun
Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
2010 Mar-Apr
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
2010 May
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
2010 May 20
Does race affect outcomes in triple negative breast cancer?
2010 May 7
Molecule of the month. Olaparib.
2010 Nov
Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
2010 Nov
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
2010 Nov 25
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
2010 Nov 9
Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.
2010 Oct
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
2010 Oct
New developments in treatment of ovarian carcinoma: focus on trabectedin.
2010 Oct 1
Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.
2010 Oct 14
Treatment options for patients with triple-negative breast cancer.
2010 Oct 27
Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
2010 Oct 5
Gateways to clinical trials.
2010 Sep
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
2010 Sep
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
2011
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
2011 Apr 14
MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.
2011 Apr 8
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
2011 Jul
BAP1 loss defines a new class of renal cell carcinoma.
2012 Jun 10
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
2012 Nov 1
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
2014 Jun
5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53.
2015 Dec 22
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
2015 Oct 29
Patents

Sample Use Guides

400 mg (eight 50 mg capsules) taken twice daily, for a total daily dose of 800 mg. Continue treatment until disease progression or unacceptable toxicity.
Route of Administration: Oral
30-100 nM in SW620 cells
Name Type Language
OLAPARIB
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
AZD2281
Code English
KEYLYNK-010 COMPONENT OLAPARIB
Code English
OLAPARIB [USAN]
Common Name English
OLAPARIB [ORANGE BOOK]
Common Name English
OLAPARIB [WHO-DD]
Common Name English
NSC-747856
Code English
OLAPARIB [JAN]
Common Name English
AZ2281
Code English
OLAPARIB [VANDF]
Common Name English
KU-0059436
Code English
OLAPARIB [INN]
Common Name English
1(2H)-PHTHALAZINONE, 4-((3-((4-(CYCLOPROPYLCARBONYL)-1-PIPERAZINYL)CARBONYL)-4-FLUOROPHENYL)METHYL)-
Systematic Name English
PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-
Systematic Name English
LYNPARZA
Brand Name English
4-((3-((4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)PHTHALAZIN-1(2H)-ONE
Systematic Name English
AZD-2281
Code English
OLAPARIB [MI]
Common Name English
KU-59436
Code English
OLAPARIB COMPONENT OF KEYLYNK-010
Code English
OLAPARIB [MART.]
Common Name English
AZ-2281
Code English
Classification Tree Code System Code
NDF-RT N0000191623
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
EMA ASSESSMENT REPORTS LYNPARZA (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
FDA ORPHAN DRUG 417613
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
EU-Orphan Drug EU/3/07/501
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
FDA ORPHAN DRUG 409213
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
WHO-ATC L01XX46
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
FDA ORPHAN DRUG 655318
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
NCI_THESAURUS C62554
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
FDA ORPHAN DRUG 419013
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
Code System Code Type Description
EVMPD
SUB32234
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
MERCK INDEX
M8185
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL521686
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
DRUG CENTRAL
4907
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
NCI_THESAURUS
C71721
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
INN
8685
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
RXCUI
1597582
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY RxNorm
IUPHAR
7519
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
FDA UNII
WOH1JD9AR8
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
CAS
763113-22-0
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
PUBCHEM
23725625
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
DRUG BANK
DB09074
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
MESH
C531550
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
LACTMED
Olaparib
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
WIKIPEDIA
OLAPARIB
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY
NDF-RT
N0000191622
Created by admin on Fri Jun 25 21:54:31 UTC 2021 , Edited by admin on Fri Jun 25 21:54:31 UTC 2021
PRIMARY Poly(ADP-Ribose) Polymerase Inhibitors [MoA]